Insulin Resistance Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH23 | Last Updated On: Jun 13 2022 | Available Formats

> Global Insulin Resistance Market Expected to reach a high CAGR of 8.24% during the forecast period 2022-2029: DataM Intelligence

Global Insulin Resistance Market is segmented by Drug Class (Biguanides, Glucagon-like Peptide 1 (GLP-1) Receptor Agonists, Concentrated Insulin Products, Sodium-glucose cotransporter 2 (SGLT2) inhibitors, and Others), By Drug Type (Branded, Generics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Market Overview

The Global Insulin Resistance Market is expected to grow at a CAGR of 8.24% during the forecasting period (2022-2029).

  • Insulin is a hormone produced in the pancreas that plays a significant role in metabolism.

  • In insulin resistance (IR), muscle, fat, and liver cells do not respond appropriately to insulin and thus cannot easily absorb glucose from the bloodstream.

  • Over time, insulin resistance can lead to type 2 diabetes, pre-diabetes, obesity, polycystic ovaries, and chronic kidney disease.

Market Growth and Trends

  • Some factors driving the market growth are increasing the prevalence of diabetes and obesity, the rise in sedentary lifestyle, and government initiatives to encourage research on diabetes and insulin resistance.

  • However, inadequate information on insulin resistance, availability of limited drugs, and widespread use of off-label drugs is likely to affect market growth.

  • There are currently no guidelines to treat patients with severe insulin resistance. Until recently, insulin was the only therapy available to treat those with severe insulin resistance.

Market Segmentation

  • Global Insulin Resistance market report segments the market by drug class, by drug type, and by region.

  • Based on drug class, the market is segmented into Biguanides, Thiazolidinediones, Corticosteroids, Insulin, Lipase Inhibitors, Glucagon-like Peptide-1 Agonists.

  • Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia PacificandRoW.

  • North America dominated the market in 2017 owing to the high prevalence of diabetes and obesity.

  • In the US, an estimated 60-70 million individuals are affected by insulin resistance.

  • The report also profiles companies in the Insulin Resistance market –AstraZeneca PLC, Biocon, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Sanofi-Aventis, and so on.

The Insulin Resistance Market Scope of the segmentation

By Drug Class

  • Biguanides

  • Thiazolidinediones

  • Corticosteroids

  • Insulin

  • Lipase Inhibitors

  • Glucagon-like Peptide-1 Agonists

  • Others

By Drug Type

  • Branded

  • Generics

By Region

  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

  • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

  • North America (The USA, Canada, Mexico)

  • South America (Brazil, Argentina, Rest of South America)

  • Rest of the World

Trending Topics

Insulin Pen Market

Insulin Delivery Devices Market

Remote Patient Monitoring Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest